Thioderon (Mepitiostane): A Comprehensive Profile for Bodybuilding and Athletic Enhancement

Thioderon Background and History

Thioderon is the brand name for the oral steroid mepitiostane, which was first developed in the 1960s. It was intended for medical use but never gained much therapeutic adoption. Bodybuilders experimented with Thioderon in the 1970s and 80s for its reputation of increasing muscle mass while avoiding estrogenic activity. However, supply remained very limited.

Chemical Structure

The active compound in Thioderon is mepitiostane, which has a structure similar to Winstrol but with a thioether group instead of the 3-keto group. This aimed to reduce potential estrogenic side effects while retaining anabolic potency. It also contains a 17-alpha-methyl group to enable oral dosing.

Dosages and Cycles

Effective Thioderon doses are in the range of 10-40mg daily taken orally. Cycles typically last 4-6 weeks followed by an equal amount of time off. Stacking with other steroids is common practice. Doses higher than 40mg increase toxicity risks substantially.

Effects and Benefits

Thioderon is valued for its ability to increase nitrogen retention and lean tissue growth without aromatizing to estrogen or converting to DHT. Gains of 5-12 pounds of solid muscle are possible in one cycle. Strength levels also increase notably.

Side Effects and Health Risks

However, possible side effects may include:

- Liver toxicity and strain

- Androgenic effects like oily skin, acne, hair loss

- Disruption of natural hormone levels

- Cholesterol imbalances

- Testosterone suppression

Proper dosing, cycle length, and stacking helps mitigate adverse reactions.

Legal Status

While it was researched for medical applications, Thioderon was never officially approved as a prescription drug. It remains classified as an illegal substance in most regions. Underground manufacturing and black market trade continues to defy prohibition.

In summary, Thioderon is an obscure oral steroid that was intended to provide lean mass gains with reduced estrogenic activity, but responsible use is imperative given its unapproved status.